Low rates of screening and treatment of chronic hepatitis B, C, D (HBV, HCV, HDV), and hepatocellular carcinoma (HCC), associated barriers, and proposed solutions: results of a survey of physicians from all major provinces of Mongolia
Guardado en:
Autores principales: | J. Estevez, Y.A. Kim, A. Le, D. Israelski, O. Baatarkhuu, T. Sarantuya, S. Narantsetseg, P. Nymadawa, H. Le, M.F. Yuen, G. Dusheiko, M. Rizzetto, M.H. Nguyen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Ubiquity Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/36af63c8365441aeae6d7e9255f485f5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Need for continuing medical education for liver disease management in Mongolia
por: Y.A. Kim, et al.
Publicado: (2016) -
Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista D, et al.
Publicado: (2021) -
MOLECULAR EPIDEMIOLOGY FEATURES OF HBV/HDV CO-INFECTION IN KYRGYZSTAN
por: A. V. Semenov, et al.
Publicado: (2016) -
Prevalence of anti HDV in HBV carriers in Babol during 2000-02
por: MR Hassanjani Roshan, et al.
Publicado: (2004) -
Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice
por: Katja Giersch, et al.
Publicado: (2017)